HK1101065A1 - - Google Patents

Info

Publication number
HK1101065A1
HK1101065A1 HK07108749.0A HK07108749A HK1101065A1 HK 1101065 A1 HK1101065 A1 HK 1101065A1 HK 07108749 A HK07108749 A HK 07108749A HK 1101065 A1 HK1101065 A1 HK 1101065A1
Authority
HK
Hong Kong
Prior art keywords
alk
alkyl
alkoxy
coor
carboxy
Prior art date
Application number
HK07108749.0A
Other languages
English (en)
Inventor
Badorc Alain
Bono Francoise
Bordes Marie-Francoise
Foidart Jean Michel
Guillo Nathalie
Noel Agnes
Rakic Jean Marie
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1101065A1 publication Critical patent/HK1101065A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
HK07108749.0A 2004-02-05 2007-08-13 HK1101065A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401094A FR2865934B1 (fr) 2004-02-05 2004-02-05 Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
PCT/FR2005/000253 WO2005082457A2 (fr) 2004-02-05 2005-02-04 Utilisation de derives d’indolizine 1,2,3 substitues pour le traitement de maladies liees à une angiogenese pathologique choroïdienne.

Publications (1)

Publication Number Publication Date
HK1101065A1 true HK1101065A1 (ja) 2007-10-05

Family

ID=34778525

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07108749.0A HK1101065A1 (ja) 2004-02-05 2007-08-13

Country Status (21)

Country Link
US (1) US8034828B2 (ja)
EP (1) EP1713543B1 (ja)
JP (1) JP5268258B2 (ja)
KR (1) KR101199730B1 (ja)
CN (1) CN1917922B (ja)
AT (1) ATE448003T1 (ja)
AU (1) AU2005216671B2 (ja)
BR (1) BRPI0507509A (ja)
CA (1) CA2553895C (ja)
CY (1) CY1109669T1 (ja)
DE (1) DE602005017581D1 (ja)
DK (1) DK1713543T3 (ja)
ES (1) ES2335900T3 (ja)
FR (1) FR2865934B1 (ja)
HK (1) HK1101065A1 (ja)
HR (1) HRP20100030T1 (ja)
IL (1) IL177088A (ja)
PL (1) PL1713543T3 (ja)
PT (1) PT1713543E (ja)
SI (1) SI1713543T1 (ja)
WO (1) WO2005082457A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100120717A1 (en) * 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838123B1 (fr) 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf

Also Published As

Publication number Publication date
CN1917922A (zh) 2007-02-21
FR2865934A1 (fr) 2005-08-12
DK1713543T3 (da) 2010-03-22
AU2005216671B2 (en) 2010-09-16
EP1713543A2 (fr) 2006-10-25
EP1713543B1 (fr) 2009-11-11
CA2553895C (fr) 2013-04-02
ATE448003T1 (de) 2009-11-15
WO2005082457A3 (fr) 2005-11-10
HRP20100030T1 (hr) 2010-03-31
PT1713543E (pt) 2009-12-15
IL177088A (en) 2010-12-30
CY1109669T1 (el) 2014-08-13
CN1917922B (zh) 2013-06-12
SI1713543T1 (sl) 2010-03-31
JP5268258B2 (ja) 2013-08-21
KR20070034986A (ko) 2007-03-29
KR101199730B1 (ko) 2012-11-08
ES2335900T3 (es) 2010-04-06
US20090030034A1 (en) 2009-01-29
IL177088A0 (en) 2006-12-10
US8034828B2 (en) 2011-10-11
FR2865934B1 (fr) 2006-05-05
JP2007520534A (ja) 2007-07-26
DE602005017581D1 (de) 2009-12-24
WO2005082457A2 (fr) 2005-09-09
BRPI0507509A (pt) 2007-06-26
AU2005216671A1 (en) 2005-09-09
CA2553895A1 (fr) 2005-09-09
PL1713543T3 (pl) 2010-04-30

Similar Documents

Publication Publication Date Title
CY1109669T1 (el) Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεση
BRPI0513750A (pt) 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek
WO2009063202A3 (en) Use of crth2 antagonist compounds
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
SE0202462D0 (sv) Novel use
PE20030581A1 (es) Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo
CA2592345A1 (en) Piperidine and azetidine derivatives as glyt1 inhibitors
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
DE602004005502D1 (de) Comt-inhibitoren
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
WO2007099302A3 (en) Methods of maintaining oral health in animals using morpholine derivatives
CY1109546T1 (el) Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
DE60126199D1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
TW200509917A (en) Use of growth hormone secretagogues for treatment of fibromyalgia

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170204